Association of cellular inhibitor of apoptosis protein-2 expression with clinical outcomes of hepatocellular carcinoma.
- Author:
Minping BI
1
;
Dinghua YANG
;
Xianghong LI
;
Kebo ZHONG
;
Yan LIU
;
Guanghui LI
;
Xiaoming LIAO
;
Xiao LIU
Author Information
- Publication Type:Journal Article
- MeSH: Baculoviral IAP Repeat-Containing 3 Protein; Carcinoma, Hepatocellular; metabolism; pathology; Female; Humans; Inhibitor of Apoptosis Proteins; metabolism; Liver Neoplasms; metabolism; pathology; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Ubiquitin-Protein Ligases
- From: Journal of Southern Medical University 2012;32(7):1020-1030
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the expression of cellular inhibitor of apoptosis protein-2 (C-IAP2) mRNA and protein in hepatocellular carcinoma (HCC) and its relationship with the clinical outcomes.
METHODSQuantitative PCR and immunohistochemical staining were used to detect the expression of C-IAP2 mRNA and protein in the tumor tissues and corresponding adjacent non-cancerous tissues from HCC patients.
RESULTSThe expression of C-IAP2 mRNA in HCC tissues was 2.70 folds higher than that in the non-cancerous tissues (P<0.001). The expression rate of C-IAP2 protein in HCC tissues was 70.8%, significantly higher than that in the non-cancerous tissues (27.8%, P=0.001). The expression of C-IAP2 mRNA and protein was associated with the tumor emboli, lymph node metastasis, AFP level, histological differentiation, TNM stage, postoperative recurrence and metastasis (P<0.05), but not with the patients' gender, age, HbsAg positivity, number of tumors, cirrhosis or the presence of tumor encapsulation (P>0.05).
CONCLUSIONThe expression of C-IAP2 in HCC is associated with tumor recurrence and metastasis, and can be a biological marker for prognostic evaluation of HCC.
